Versant Venture Management, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 11, 2025), Versant Venture Management, LLC reported 8 stock positions worth $82.1 million. Its top holding was Monte Rosa Therapeutics (GLUE) at 31.0% of the portfolio, followed by Crispr Therapeutics (CRSP, 29.5%) and Jade Biosciences (JBIO, 18.6%). Compared with Q1 2025, it opened 2 new positions, sold out of 1 and reduced 1. The biggest buy was a new position in Jade Biosciences (JBIO) and the biggest sale Contineum Therapeutics Class A (CTNM, shares −41%).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001560009
- Portfolio Value
- $82.1M (Q2 2025)
- SEC Filing
- 0000950123-25-007471 ↗ filed Aug 11, 2025
Holdings Value
Holdings 8 stocks · $82.1M
| GLUE Monte Rosa Therapeutics Inc. | 31.04% | 5,652,922 | $25.5M | No change |
| CRSP Crispr Therapeutics AG | 29.52% | 498,558 | $24.2M | No change |
| JBIO Jade Biosciences Inc. | 18.56% | 1,525,820 | $15.2M | New |
| SKYE Skye Bioscience Inc. | 10.22% | 2,007,704 | $8.4M | No change |
| RPTX Repare Therapeutics Inc. | 4.48% | 2,646,657 | $3.7M | No change |
| CTNM Contineum Therapeutics Inc. Class A | 2.62% | 542,628 | $2.2M | Reduce -40.9% |
| TPST Tempest Therapeutics Inc. | 2.23% | 269,772 | $1.8M | New |
| ADVM Adverum Biotechnologies Inc. | 1.33% | 506,821 | $1.1M | No change |
Portfolio Sells Q1 2025 → Q2 2025
Portfolio Buys Q1 2025 → Q2 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 8 | $162.6M | GLUE, IPSC, JBIO, LENZ, CTNM |
| Q1 2026 | 8 | $141.4M | GLUE, IPSC, LENZ, JBIO, CTNM |
| Q4 2025 | 7 | $151.1M | GLUE, LENZ, JBIO, CRSP, CTNM |
| Q3 2025 | 9 | $212.5M | LENZ, GLUE, JBIO, CRSP, SKYE |
| Q2 2025 | 8 | $82.1M | GLUE, CRSP, JBIO, SKYE, RPTX |
| Q1 2025 | 7 | $60.2M | GLUE, CRSP, CTNM, SKYE, RPTX |
| Q4 2024 | 7 | $86.7M | GLUE, CRSP, CTNM, SKYE, RPTX |
| Q3 2024 | 6 | $63.6M | CRSP, CTNM, RPTX, SKYE, ADVM |
| Q2 2024 | 8 | $77.3M | CRSP, CTNM, SKYE, RPTX, ADVM |
| Q1 2024 | 7 | $103.1M | CRSP, SKYE, RPTX, GRITSTONE BIO INC, ADVM |